Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00777153 · ClinicalTrials.gov registry record · Phase 3

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

A Phase 3 study of Recurrent Glioblastoma, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
423
Enrollment target
20
Study locations

NCT00777153 is a Phase 3 study of Recurrent Glioblastoma that has completed, run by AstraZeneca. The registered enrollment target is 423 participants, above the 62-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (582% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00777153, a Phase 3 study of Recurrent Glioblastoma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
423 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.

Conditions Studied

Recurrent Glioblastoma

Interventions

  • DRUG Cediranib
  • DRUG Lomustine Chemotherapy
  • DRUG Placebo Cediranib

Study Locations (20)

Ohio

  • Research Site - Cincinnati
  • Research Site - Cleveland
  • Research Site - Columbus

Florida

  • Research Site - Gainesville
  • Research Site - Jacksonville

Illinois

  • Research Site - Chicago
  • Research Site - Evanston

New York

  • Research Site - Amherst
  • Research Site - New York

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Pittsburgh

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Pheonix

California

  • Research Site - Los Angeles

Trial Details

FieldValue
Enrollment Target 423 participants
Start Date 2008-10
Est. Completion 2016-09
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00777153

The ClinicalTrials.gov registry entry for NCT00777153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (582% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Cediranib is the first listed.

NCT00777153 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT00777153 about?

NCT00777153 is a clinical study titled "Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma". The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has ...

What is the current status of trial NCT00777153?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 423 participants. The study started on 2008-10. Estimated completion is 2016-09.

What conditions does trial NCT00777153 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma.

What interventions are being tested in trial NCT00777153?

The interventions under investigation include: Cediranib (DRUG), Lomustine Chemotherapy (DRUG), Placebo Cediranib (DRUG).

Who is sponsoring clinical trial NCT00777153?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00777153 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.